256 related articles for article (PubMed ID: 23973342)
1. A maternal vaccine against group B Streptococcus: past, present, and future.
Chen VL; Avci FY; Kasper DL
Vaccine; 2013 Aug; 31 Suppl 4(0 4):D13-9. PubMed ID: 23973342
[TBL] [Abstract][Full Text] [Related]
2. The spectrum of perinatal group B streptococcal disease.
Baker CJ
Vaccine; 2013 Aug; 31 Suppl 4():D3-6. PubMed ID: 23973344
[TBL] [Abstract][Full Text] [Related]
3. Systematic review of the clinical development of group B streptococcus serotype-specific capsular polysaccharide-based vaccines.
Dzanibe S; Madhi SA
Expert Rev Vaccines; 2018 Jul; 17(7):635-651. PubMed ID: 29961350
[TBL] [Abstract][Full Text] [Related]
4. Alpha C protein as a carrier for type III capsular polysaccharide and as a protective protein in group B streptococcal vaccines.
Gravekamp C; Kasper DL; Paoletti LC; Madoff LC
Infect Immun; 1999 May; 67(5):2491-6. PubMed ID: 10225912
[TBL] [Abstract][Full Text] [Related]
5. A Phase 2, Randomized, Control Trial of Group B Streptococcus (GBS) Type III Capsular Polysaccharide-tetanus Toxoid (GBS III-TT) Vaccine to Prevent Vaginal Colonization With GBS III.
Hillier SL; Ferrieri P; Edwards MS; Ewell M; Ferris D; Fine P; Carey V; Meyn L; Hoagland D; Kasper DL; Paoletti LC; Hill H; Baker CJ
Clin Infect Dis; 2019 May; 68(12):2079-2086. PubMed ID: 30281066
[TBL] [Abstract][Full Text] [Related]
6. Group B Streptococcus: developing a correlate of protection for a vaccine against neonatal infections.
Dangor Z; Lala SG; Kwatra G; Madhi SA
Curr Opin Infect Dis; 2016 Jun; 29(3):262-7. PubMed ID: 26926474
[TBL] [Abstract][Full Text] [Related]
7. Group B Streptococcus vaccination in pregnancy: moving toward a global maternal immunization program.
Munoz FM; Ferrieri P
Vaccine; 2013 Aug; 31 Suppl 4():D46-51. PubMed ID: 23176976
[TBL] [Abstract][Full Text] [Related]
8. Maternal group B streptococcal immunization: capsular polysaccharide (CPS)-based vaccines and their implications on prevention.
Palmeiro JK; De Carvalho NS; Botelho AC; Fracalanzza SE; Madeira HM; Dalla-Costa LM
Vaccine; 2011 May; 29(21):3729-30. PubMed ID: 21414381
[TBL] [Abstract][Full Text] [Related]
9. Intrapartum antibiotic prophylaxis for the prevention of perinatal group B streptococcal disease: experience in the United States and implications for a potential group B streptococcal vaccine.
Schrag SJ; Verani JR
Vaccine; 2013 Aug; 31 Suppl 4():D20-6. PubMed ID: 23219695
[TBL] [Abstract][Full Text] [Related]
10. Preventing the broad spectrum of perinatal morbidity and mortality through group B streptococcal vaccination.
Edwards MS; Gonik B
Vaccine; 2013 Aug; 31 Suppl 4():D66-71. PubMed ID: 23200934
[TBL] [Abstract][Full Text] [Related]
11. A Novel Hexavalent Capsular Polysaccharide Conjugate Vaccine (GBS6) for the Prevention of Neonatal Group B Streptococcal Infections by Maternal Immunization.
Buurman ET; Timofeyeva Y; Gu J; Kim JH; Kodali S; Liu Y; Mininni T; Moghazeh S; Pavliakova D; Singer C; Singh S; Handke LD; Lotvin J; Prasad AK; Scully IL; Donald RGK; Jansen KU; Anderson AS
J Infect Dis; 2019 Jun; 220(1):105-115. PubMed ID: 30778554
[TBL] [Abstract][Full Text] [Related]
12. Use of type V group B streptococcal conjugate vaccine in adults 65-85 years old.
Palazzi DL; Rench MA; Edwards MS; Baker CJ
J Infect Dis; 2004 Aug; 190(3):558-64. PubMed ID: 15243932
[TBL] [Abstract][Full Text] [Related]
13. An update on vaccination against group B streptococcus.
Heath PT
Expert Rev Vaccines; 2011 May; 10(5):685-94. PubMed ID: 21604988
[TBL] [Abstract][Full Text] [Related]
14. Dose-response to type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine in healthy adults.
Baker CJ; Rench MA; Paoletti LC; Edwards MS
Vaccine; 2007 Jan; 25(1):55-63. PubMed ID: 16919857
[TBL] [Abstract][Full Text] [Related]
15. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine.
Kasper DL; Paoletti LC; Wessels MR; Guttormsen HK; Carey VJ; Jennings HJ; Baker CJ
J Clin Invest; 1996 Nov; 98(10):2308-14. PubMed ID: 8941648
[TBL] [Abstract][Full Text] [Related]
16. Considerations for a phase-III trial to evaluate a group B Streptococcus polysaccharide-protein conjugate vaccine in pregnant women for the prevention of early- and late-onset invasive disease in young-infants.
Madhi SA; Dangor Z; Heath PT; Schrag S; Izu A; Sobanjo-Ter Meulen A; Dull PM
Vaccine; 2013 Aug; 31 Suppl 4():D52-7. PubMed ID: 23973347
[TBL] [Abstract][Full Text] [Related]
17. Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine.
Paoletti LC; Wessels MR; Rodewald AK; Shroff AA; Jennings HJ; Kasper DL
Infect Immun; 1994 Aug; 62(8):3236-43. PubMed ID: 8039893
[TBL] [Abstract][Full Text] [Related]
18. Group B streptococcal epidemiology and vaccine needs in developed countries.
Melin P; Efstratiou A
Vaccine; 2013 Aug; 31 Suppl 4():D31-42. PubMed ID: 23973345
[TBL] [Abstract][Full Text] [Related]
19. Group B streptococcal vaccines.
Baker CJ; Kasper DL
Rev Infect Dis; 1985; 7(4):458-67. PubMed ID: 3898306
[TBL] [Abstract][Full Text] [Related]
20. Preparation and preclinical evaluation of experimental group B streptococcus type III polysaccharide-cholera toxin B subunit conjugate vaccine for intranasal immunization.
Shen X; Lagergård T; Yang Y; Lindblad M; Fredriksson M; Holmgren J
Vaccine; 2000 Nov; 19(7-8):850-61. PubMed ID: 11115709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
